FDA Rejects Replimune Melanoma Therapy, Citing Data Concerns

Replimune Group has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its Biologics License Application (BLA) seeking approval of RP1 in combination with nivolumab for the treatment of advanced melanoma, dealing a significant setback to the company’s lead cancer therapy.

The CRL indicates that the FDA will not approve the application in its current form, citing concerns over the sufficiency of the clinical data package. The decision comes despite earlier regulatory signals that had granted the therapy Breakthrough Therapy Designation, raising expectations for a potential accelerated approval pathway.

RP1 is an investigational oncolytic immunotherapy designed to selectively infect and destroy cancer cells while stimulating the immune system. In combination with nivolumab, a widely used immune checkpoint inhibitor, the therapy was evaluated in the Phase 2 IGNYTE trial involving patients with advanced melanoma who had progressed on prior anti-PD-1 treatments.

According to the company, results from the IGNYTE trial showed a 34% response rate, with a median duration of response of 24.8 months, alongside a favorable safety profile. These outcomes had positioned the therapy as a potentially meaningful option for patients with limited treatment alternatives.

However, Replimune strongly disagreed with the FDA’s assessment, arguing that the data supporting the application were sufficient for approval under accelerated pathways. Sushil Patel expressed deep disappointment with the agency’s decision, highlighting what he described as inconsistent communication and a lack of regulatory flexibility.

He further emphasized the urgent need for new treatments, noting that approximately 8,500 patients in the United States die from advanced melanoma each year. Patel warned that without timely approval, continued development of RP1 may no longer be viable, forcing the company to scale back operations and eliminate jobs, including significant reductions in its U.S.-based manufacturing activities.

The company also raised concerns about the regulatory review process, stating that a new FDA review team was assigned during the resubmission phase, replacing the original team that had previously engaged with Replimune. According to the company, this shift contributed to differing interpretations of the clinical data and regulatory expectations.

Replimune pointed to several instances where it believes the FDA’s current position contradicts earlier feedback, including discussions around trial design, patient population, and the acceptability of single-arm studies for accelerated approval. The company noted that it had followed prior agency guidance, including conducting tumor assessments using standardized RECIST 1.1 criteria and initiating a confirmatory Phase 3 trial, IGNYTE-3.

Despite the setback, the broader development program for RP1 underscores the growing interest in oncolytic immunotherapies as a novel approach to cancer treatment. Whether Replimune can address the FDA’s concerns and resubmit its application remains uncertain, but the decision highlights the challenges biotech companies face in navigating complex regulatory pathways while striving to bring innovative therapies to patients in need.